DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

starempty starempty starempty starempty star (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment



Molecular Imaging Homepage

New PET imaging method may yield benefits over FDG for detecting certain cancers Gallium-68-labeled FAPI tracer yields promising results

Dr. David Wong Professor recognized for contributions to PET and Theranostics

SVSR unveils Siemens Horizon PET/CT trailer Putting a small and powerful scanner on a coach

Philips to manage medical imaging equipment for Aussie providers for 20 years First-of-its-kind partnership in Australia and ASEAN Pacific region

Under AMG, Piramal Imaging changes name to Life Molecular Imaging LMI is being run within the Alliance Medical Molecular Imaging division

RadioMedix Inc. and Curium to develop and commercialize PET agent 64Cu-Dotatate for use in suspected neuroendocrine tumors

Dr. Sanjiv Gambhir Stanford’s chair of radiology wins Cassen Prize

Researchers undertake 'largest brain study' using 60,000 SPECT images Evaluate accelerated brain aging in scans

SNMMI proposes solutions to Ga-68 generator shortage Combating waiting periods of between 14 and 18 months

Tc-99m generator production resumes in Australia Follows month and a half shutdown due to conveyor belt issue

Rick Rippin

New technologies to help expand PET/CT imaging in emerging markets

An editorial by Rick Rippin

PET/CT is an important modality today in oncology, and there has been a robust growth in the installation of cyclotrons and PET/CT scanners in developed countries, where the strategy has been to establish centralized radiopharmacies to supply 18FDG to facilities within a distribution grid.

Establishing a conventional cyclotron can be complex due to the significant infrastructure and equipment costs, and the demand for specialized support.
Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

In emerging markets, this centralized distribution model is much more difficult due to economic challenges and transportation logistics. A trend towards smaller and simpler solutions has progressed, with companies offering “table top” cyclotrons with compact and automated radiochemistry units This decentralized strategy enables the users to produce on-demand doses 18FDG and other tracers using an automated and user-friendly technology, providing availability at an affordable cost to these developing countries.

One example is the BG-75 “Dose on Demand” Biomarker Generator from ABT Molecular Imaging. The company offers a 7.5Mev cyclotron with simplified single or small batch 18FDG production, and automated quality control. The solution has made it economically feasible to implement in-house radiopharmaceutical production. For example, Fundacion Valle de Lili Hospital in Cali, Columbia, was having FDG transported via airlines from a city >400 km away at considerable cost. By implementing the first Biomarker Generator System in Colombia, they were able to reduce their 18FDG costs, and expand their scheduling.

Another example can be found in the largest island in Southeast Asia. With a population of 18 million citizens, Borneo had no access to PET/CT due to lack of access to 18FDG. Borneo Medical Center used an existing 35 m2 space in their hospital to install the Biomarker Generator System, and is now the first provider to offer PET/CT.

While having economical, on-demand access to 18FDG is most important for emerging markets to initiate PET/CT, the capability to produce other more specific tracers is equally important. German Oncology Center, who also installed the first Biomarker Generator and PET/CT on the island of Cyprus, is a highly specialized, private oncology center. They not only produce 18FDG, but also other important tracers such as PSMA for prostate imaging, and FET for brain tumor imaging.

The global growth of PET/CT may well be accelerated by this decentralized approach, where hospitals and health care providers can produce on-demand doses of PET radiopharmaceuticals by installing this type of compact, automated, and user-friendly system.

About the author: Rick Rippin is the sales director for ABT Molecular Imaging

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.